ArticleMolecular biology reports2026
Hydatid cyst antigen B: inducer of inflammatory and apoptotic responses in colon cancer cell lines (SW480 and SW948).
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a major global health challenge with a high mortality rate, necessitating the identification of novel therapeutic approaches. The purified Antigen B (AgB) from hydatid cyst fluid is an immunoactive component with known abilities to modulate host immune responses. Given the increasing role of inflammatory pathways in regulating tumor progression or inhibition, this study aimed to investigate the effect of AgB on cell viability and the expression of inflammasome-related genes (including NLRP3, IL-1β, IL-8, and Caspase-1) in human colon cancer cell lines, SW480 and SW948.
methodsIn this experimental study, AgB was collected and purified from ovine hydatid cysts. The SW480 and SW948 cell lines were treated with different concentrations of AgB (10–100 µg/mL) for 24 h. Cell viability was evaluated using the MTT assay. Subsequently, the expression of NLRP3, IL-1β, IL-8, and Caspase-1 genes, as key components of the inflammasome axis, was examined using the quantitative real-time PCR (qRT-PCR) technique.
resultsThe MTT assay results showed that AgB had a dose-dependent cytotoxic effect on both cell lines, leading to a significant decrease in cell viability. The IC50 value for AgB was determined to be 150 µg/mL in both cell lines. The qRT-PCR analysis indicated a significant increase in the expression of NLRP3, IL-1β, and Caspase-1 genes in both SW480 and SW948 cell lines treated with AgB compared to the control group (P < 0.05). However, the increase in IL-8 gene expression was not statistically significant (P > 0.05). These findings suggest that AgB modulates the expression of key genes in the inflammasome pathway in colon cancer cells.
conclusionThe data from this study demonstrate that AgB can affect inflammasome-dependent pathways in colorectal cancer cell lines. These results provide a new perspective for utilizing AgB as an immunomodulatory compound in preclinical cancer studies and highlight its potential in the development of novel therapeutic strategies against colon cancer.
Indexed as
Identifiers
42047899What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.